Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2026)
Treace Medical Concepts (TMCI) posted Net Income towards Common Stockholders of -$20.8 million for Q1 2026, down 199.47% on a QoQ basis from -$7.0 million in Q4 2025, and down 29.87% year-over-year from -$29.7 million in Q1 2025.
Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Treace Medical Concepts' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$20.8 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 29.87% year-over-year to -$20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.7 million (down 15.08% YoY) and the FY2025 annual result came in at -$108.0 million, down 13.84% from the prior year.
- Net Income towards Common Stockholders was -$20.8 million for Q1 2026 at Treace Medical Concepts, down from -$7.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$873000.0 in Q4 2024 and bottomed at -$21.3 million in Q2 2024.
- A 5-year average of -$13.3 million and a median of -$15.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 86.31% — and 2025, when it plunged 697.37%.
- Treace Medical Concepts' Net Income towards Common Stockholders stood at -$4.4 million in 2022, then plunged by 44.54% to -$6.4 million in 2023, then surged by 86.31% to -$873000.0 in 2024, then plunged by 697.37% to -$7.0 million in 2025, then slumped by 199.47% to -$20.8 million in 2026.
- Business Quant data shows TMCI's Net Income towards Common Stockholders at -$20.8 million in Q1 2026, -$7.0 million in Q4 2025, and -$16.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Treace Medical Concepts | 262.89 Mn | 211.04 Mn | 37.41 Mn | -20.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.85 Mn |
| Dec 31, 2025 | -6.96 Mn |
| Sep 30, 2025 | -16.38 Mn |
| Jun 30, 2025 | -17.52 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Dec 31, 2024 | -873,000.00 |
| Sep 30, 2024 | -15.38 Mn |
| Jun 30, 2024 | -21.32 Mn |
| Mar 31, 2024 | -18.75 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -17.54 Mn |
| Jun 30, 2023 | -12.37 Mn |
| Mar 31, 2023 | -13.58 Mn |
| Dec 31, 2022 | -4.41 Mn |
| Sep 30, 2022 | -12.13 Mn |
| Jun 30, 2022 | -17.23 Mn |
| Mar 31, 2022 | -9.04 Mn |
| Dec 31, 2021 | -6.62 Mn |
| Sep 30, 2021 | -6.42 Mn |
| Jun 30, 2021 | -5.12 Mn |